These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 22086720)

  • 1. Sirtuin 1 (SIRT1): the misunderstood HDAC.
    Stünkel W; Campbell RM
    J Biomol Screen; 2011 Dec; 16(10):1153-69. PubMed ID: 22086720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SIRTUIN 1: regulating the regulator.
    Zschoernig B; Mahlknecht U
    Biochem Biophys Res Commun; 2008 Nov; 376(2):251-5. PubMed ID: 18774777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIRT1 and SIRT2: emerging targets in neurodegeneration.
    Donmez G; Outeiro TF
    EMBO Mol Med; 2013 Mar; 5(3):344-52. PubMed ID: 23417962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How much successful are the medicinal chemists in modulation of SIRT1: A critical review.
    Kumar A; Chauhan S
    Eur J Med Chem; 2016 Aug; 119():45-69. PubMed ID: 27153347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carprofen analogues as sirtuin inhibitors: enzyme and cellular studies.
    Mellini P; Carafa V; Di Rienzo B; Rotili D; De Vita D; Cirilli R; Gallinella B; Provvisiero DP; Di Maro S; Novellino E; Altucci L; Mai A
    ChemMedChem; 2012 Nov; 7(11):1905-8. PubMed ID: 24155041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.
    Lara E; Mai A; Calvanese V; Altucci L; Lopez-Nieva P; Martinez-Chantar ML; Varela-Rey M; Rotili D; Nebbioso A; Ropero S; Montoya G; Oyarzabal J; Velasco S; Serrano M; Witt M; Villar-Garea A; Imhof A; Mato JM; Esteller M; Fraga MF
    Oncogene; 2009 Feb; 28(6):781-91. PubMed ID: 19060927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirtuin activators.
    Alcaín FJ; Villalba JM
    Expert Opin Ther Pat; 2009 Apr; 19(4):403-14. PubMed ID: 19441923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirtuin inhibitors.
    Alcaín FJ; Villalba JM
    Expert Opin Ther Pat; 2009 Mar; 19(3):283-94. PubMed ID: 19441904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of the cellular deacetylase activity of SIRT1 on p53 via LanthaScreen® technology.
    Robers MB; Loh C; Carlson CB; Yang H; Frey EA; Hermanson SB; Bi K
    Mol Biosyst; 2011 Jan; 7(1):59-66. PubMed ID: 20931131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183.
    Huber JL; McBurney MW; Distefano PS; McDonagh T
    Future Med Chem; 2010 Dec; 2(12):1751-9. PubMed ID: 21428798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors.
    Mai A; Valente S; Meade S; Carafa V; Tardugno M; Nebbioso A; Galmozzi A; Mitro N; De Fabiani E; Altucci L; Kazantsev A
    J Med Chem; 2009 Sep; 52(17):5496-504. PubMed ID: 19663498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The critical role of the class III histone deacetylase SIRT1 in cancer.
    Liu T; Liu PY; Marshall GM
    Cancer Res; 2009 Mar; 69(5):1702-5. PubMed ID: 19244112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirtuins and p53.
    van Leeuwen I; Lain S
    Adv Cancer Res; 2009; 102():171-95. PubMed ID: 19595309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases.
    Knutson MD; Leeuwenburgh C
    Nutr Rev; 2008 Oct; 66(10):591-6. PubMed ID: 18826454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of activators and inhibitors of sirtuins.
    Balcerczyk A; Pirola L
    Biofactors; 2010; 36(5):383-93. PubMed ID: 20848588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capillary electrophoresis-based sirtuin assay using non-peptide substrates.
    Fan Y; Hense M; Ludewig R; Weisgerber C; Scriba GK
    J Pharm Biomed Anal; 2011 Mar; 54(4):772-8. PubMed ID: 21074959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
    Li G; Jiang H; Chang M; Xie H; Hu L
    J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirtuin modulators: an updated patent review (2012 - 2014).
    Mellini P; Valente S; Mai A
    Expert Opin Ther Pat; 2015 Jan; 25(1):5-15. PubMed ID: 25435179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.
    Napper AD; Hixon J; McDonagh T; Keavey K; Pons JF; Barker J; Yau WT; Amouzegh P; Flegg A; Hamelin E; Thomas RJ; Kates M; Jones S; Navia MA; Saunders JO; DiStefano PS; Curtis R
    J Med Chem; 2005 Dec; 48(25):8045-54. PubMed ID: 16335928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirtuin activators and inhibitors.
    Villalba JM; Alcaín FJ
    Biofactors; 2012; 38(5):349-59. PubMed ID: 22730114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.